Oramed defers Scilex $6.25M amortization; receives 2.5M free-trading Scilex shares

ORAMED PHARMACEUTICALS INC.

Initial $6.25M amortization due Jan 2, 2025 deferred to Jan 31; further deferral to Oct 2026 conditional on royalty grant.
Oramed receives 2.5M of 5M free-trading Scilex shares from SCLX JV as consideration for the deferral.
Term sheet contemplates 4% royalty on global net sales of Gloperba and Elyxyb (ex-Canada) for 10 years.
Scilex must extend $25M promissory note maturity to Dec 31, 2025; Oramed has discretion on terms.
$1.11M cash paid to noteholders for portion of amortization and make-whole interest.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.